Vir Biotechnology (VIR) Competitors $5.26 +0.09 (+1.74%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$5.24 -0.01 (-0.29%) As of 09/24/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIR vs. OGN, KNSA, NAMS, BHC, GMTX, CGON, MLYS, IBRX, CPRX, and ALVOShould you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), CG Oncology (CGON), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Vir Biotechnology vs. Its Competitors Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Vir Biotechnology (NASDAQ:VIR) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Which has more risk & volatility, VIR or OGN? Vir Biotechnology has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Does the media refer more to VIR or OGN? In the previous week, Vir Biotechnology and Vir Biotechnology both had 3 articles in the media. Vir Biotechnology's average media sentiment score of 1.35 beat Organon & Co.'s score of 1.16 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in VIR or OGN? 65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VIR or OGN more profitable? Organon & Co. has a net margin of 11.15% compared to Vir Biotechnology's net margin of -2,895.94%. Organon & Co.'s return on equity of 163.88% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Vir Biotechnology-2,895.94% -50.22% -40.78% Organon & Co. 11.15%163.88%6.99% Do analysts rate VIR or OGN? Vir Biotechnology currently has a consensus target price of $17.30, indicating a potential upside of 228.90%. Organon & Co. has a consensus target price of $17.33, indicating a potential upside of 66.35%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Organon & Co. 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has higher earnings and valuation, VIR or OGN? Organon & Co. has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVir Biotechnology$74.21M9.85-$521.96M-$4.00-1.32Organon & Co.$6.40B0.42$864M$2.693.87 SummaryOrganon & Co. beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks. Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIR vs. The Competition Export to ExcelMetricVir BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$718.20M$3.15B$5.77B$10.42BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-1.3220.7676.2826.42Price / Sales9.85444.26552.28127.65Price / CashN/A45.9137.5661.52Price / Book0.639.8313.186.39Net Income-$521.96M-$52.73M$3.29B$271.13M7 Day Performance1.54%1.84%0.84%0.93%1 Month Performance20.09%7.48%5.03%7.52%1 Year Performance-27.55%19.92%71.27%30.06% Vir Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRVir Biotechnology3.5517 of 5 stars$5.26+1.7%$17.30+228.9%-30.2%$718.20M$74.21M-1.32580Positive NewsOGNOrganon & Co.4.5618 of 5 stars$10.39-2.5%$17.33+66.9%-47.1%$2.77B$6.40B3.024,000Positive NewsKNSAKiniksa Pharmaceuticals International2.7294 of 5 stars$36.56-1.5%$41.17+12.6%+47.6%$2.75B$423.24M914.23220Positive NewsNAMSNewAmsterdam Pharma3.0905 of 5 stars$24.12-0.3%$41.55+72.2%+72.1%$2.72B$45.56M0.004Positive NewsBHCBausch Health Cos4.601 of 5 stars$7.17-1.2%$9.00+25.5%-17.6%$2.69B$9.63B27.5820,700GMTXGemini TherapeuticsN/A$59.82-0.8%N/A+32.4%$2.59BN/A-59.8230CGONCG Oncology2.5585 of 5 stars$34.60+3.8%$53.91+55.8%+0.4%$2.54B$1.14M0.0061Insider TradeMLYSMineralys Therapeutics2.7079 of 5 stars$36.21-2.4%$43.50+20.1%+232.2%$2.46BN/A0.0028Positive NewsIBRXImmunityBio2.3037 of 5 stars$2.74+5.4%$10.75+292.3%-30.6%$2.46B$14.74M0.00590High Trading VolumeCPRXCatalyst Pharmaceuticals4.9414 of 5 stars$19.76-1.1%$33.20+68.0%-3.9%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.4889 of 5 stars$8.12+1.1%$14.00+72.4%-23.2%$2.42B$491.98M18.251,032Trending NewsAnalyst Upgrade Related Companies and Tools Related Companies OGN Alternatives KNSA Alternatives NAMS Alternatives BHC Alternatives GMTX Alternatives CGON Alternatives MLYS Alternatives IBRX Alternatives CPRX Alternatives ALVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts